Efficiency of viral DNA synthesis during infection of permissive and nonpermissive cells with vif-negative human immunodeficiency virus type 1
about
Ring finger protein ZIN interacts with human immunodeficiency virus type 1 VifThe cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNAHIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factorsHIV-1 Vif, APOBEC, and intrinsic immunityComprehensive investigation of the molecular defect in vif-deficient human immunodeficiency virus type 1 virionsFeline immunodeficiency virus Vif localizes to the nucleusInhibitors of human immunodeficiency virus type 1 reverse transcriptase target distinct phases of early reverse transcriptionMulti-scale modeling of HIV infection in vitro and APOBEC3G-based anti-retroviral therapyAPOBEC3G: an intracellular centurionImplication of the lymphocyte-specific nuclear body protein Sp140 in an innate response to human immunodeficiency virus type 1.Mass spectrometry analysis of HIV-1 Vif reveals an increase in ordered structure upon oligomerization in regions necessary for viral infectivity.APOBEC3G inhibits elongation of HIV-1 reverse transcripts.Association of human immunodeficiency virus type 1 Vif with RNA and its role in reverse transcriptionHuman immunodeficiency virus type 1 integrase protein promotes reverse transcription through specific interactions with the nucleoprotein reverse transcription complex.Functional domains of Tat required for efficient human immunodeficiency virus type 1 reverse transcription.Role of matrix in an early postentry step in the human immunodeficiency virus type 1 life cycle.gag, vif, and nef genes contribute to the homologous viral interference induced by a nonproducer human immunodeficiency virus type 1 (HIV-1) variant: identification of novel HIV-1-inhibiting viral protein mutants.Human immunodeficiency virus type 1 replication is modulated by host cyclophilin A expression levels.Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics.Vif is largely absent from human immunodeficiency virus type 1 mature virions and associates mainly with viral particles containing unprocessed gag.Human immunodeficiency virus type 1 Vif protein is packaged into the nucleoprotein complex through an interaction with viral genomic RNA.Cytoskeleton association and virion incorporation of the human immunodeficiency virus type 1 Vif protein.Conservation of an intact vif gene of human immunodeficiency virus type 1 during maternal-fetal transmission.Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding.Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins.Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by a two-amino-acid insertion in HIV-1 Vif from a nonprogressing mother and child.Human immunodeficiency virus type 1 Vif is efficiently packaged into virions during productive but not chronic infection.Amino acid residues 88 and 89 in the central hydrophilic region of human immunodeficiency virus type 1 Vif are critical for viral infectivity by enhancing the steady-state expression of Vif.Biochemical activities of highly purified, catalytically active human APOBEC3G: correlation with antiviral effect.The role of BST2/tetherin in feline retrovirus infectionAPOBEC3G-Augmented Stem Cell Therapy to Modulate HIV Replication: A Computational Study.Resistance of human T cell leukemia virus type 1 to APOBEC3G restriction is mediated by elements in nucleocapsidConservation of an intact human immunodeficiency virus type 1 vif gene in vitro and in vivoThe vif gene is essential for efficient replication of caprine arthritis encephalitis virus in goat synovial membrane cells and affects the late steps of the virus replication cycleAberrant Gag protein composition of a human immunodeficiency virus type 1 vif mutant produced in primary lymphocytesBiological activity of human immunodeficiency virus type 1 Vif requires membrane targeting by C-terminal basic domains.The Vif protein of human and simian immunodeficiency viruses is packaged into virions and associates with viral core structures.Replication and pathogenicity of human immunodeficiency virus type 1 accessory gene mutants in SCID-hu mice.Interference to human immunodeficiency virus type 1 infection in the absence of downmodulation of the principal virus receptor, CD4.The human immunodeficiency virus type 1 Vif protein modulates the postpenetration stability of viral nucleoprotein complexes
P2860
Q24304030-3152B3BE-25D7-417F-9FF7-6B2FA16BE5D0Q24305266-4F46EF9D-9CA1-4421-9CCB-C365581393B3Q24619114-5E55687D-370D-4588-A56E-3A53CBB7CDF4Q24647833-78B9CDC0-1A07-4023-9EDC-CF1EC088F933Q24678970-450BA2E6-8852-49AD-9197-E0B3FFFE602FQ27469637-58BB4A7A-AB20-421C-883C-B7AAF70BF3C5Q28359887-A6F966B5-E2D0-4B62-949E-E812BAE83840Q28480578-1395824D-7C24-464D-B328-89760451B9A3Q28754989-B7232AE8-E11A-4FDB-B3D5-CC65631CF0B0Q30860339-6887A38A-D20A-4D56-9ACF-61A94B6808DCQ33289183-40E0F886-A210-4182-BD28-C431DB01DE62Q33389841-B1A3C6ED-0289-4CD0-9203-3B3EA3B7D676Q33604247-0147F5F7-A9BF-4BFB-855F-9BDC522FB4DDQ33653264-A74DC6E7-4C7A-4ED7-ABC0-C4CBA94EA837Q33654155-51FA5136-5552-46BA-9476-CD48F57BEADFQ33782781-579BDA8E-9725-415B-971B-CC12452B38F1Q33782866-12ECA01E-8141-42A5-8429-9A1CA085AADDQ33783386-28AF4C1B-2A4F-40C1-8106-8EB874A3A0A2Q33815187-F60A0E62-8C48-4413-905D-E04E2A3F8A1EQ33841920-DCCB55A1-0A13-411D-9681-EDFEA1223FE8Q33852465-F52A1D6F-B08D-419B-A07E-31DEB6010817Q34062105-6BB5E962-CA36-44A2-9936-95AF9259F6A3Q34069296-29DC57F6-548B-4987-8A78-BF1D95538BCAQ34163065-13D8BCD3-B6DD-483F-AB81-0D8F2A9EFFF3Q34312616-B3605810-8DA8-4195-A784-D7EDE562EEACQ34348825-CDB239F6-816D-41DE-947E-0C44F4BF6CAEQ34465108-526A9B70-5663-4942-AF72-72C5DB89AAFBQ34465355-05FDC2D1-95BD-4F36-BE4D-0E5FD1A2827CQ34651434-0B3F68C7-0639-4086-8E40-BACC7CABE0C8Q34664616-6706C3D6-5489-486D-9313-31FF7BC9C602Q34749384-BA540180-C452-4EC3-A81F-247E4D44436EQ35669808-25EAD0E9-6E9D-41EE-A4F6-EF4EBAA7083CQ35838106-1DC3C209-7B8D-4D7E-B6D6-A3530382026AQ35839334-9A8870BE-E592-48C7-9C4C-4F5A4896B370Q35842465-404B2DAC-3CA4-4743-8C1C-47CAC747C549Q35851202-44CDB09E-5179-43A1-A4BD-235136810087Q35851966-692E32CE-1F69-45FA-8377-79474FB35907Q35856279-A655E793-2524-49B4-B4CD-E1D124A97CDAQ35861652-53E639DC-CA90-47AD-A385-5E1A0F629C04Q35866134-0DE6CB22-335E-4B3E-9E7C-ADD08CF98AC5
P2860
Efficiency of viral DNA synthesis during infection of permissive and nonpermissive cells with vif-negative human immunodeficiency virus type 1
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
Efficiency of viral DNA synthe ...... immunodeficiency virus type 1
@ast
Efficiency of viral DNA synthe ...... immunodeficiency virus type 1
@en
type
label
Efficiency of viral DNA synthe ...... immunodeficiency virus type 1
@ast
Efficiency of viral DNA synthe ...... immunodeficiency virus type 1
@en
prefLabel
Efficiency of viral DNA synthe ...... immunodeficiency virus type 1
@ast
Efficiency of viral DNA synthe ...... immunodeficiency virus type 1
@en
P2860
P1433
P1476
Efficiency of viral DNA synthe ...... immunodeficiency virus type 1
@en
P2093
P2860
P304
P407
P577
1993-10-01T00:00:00Z